Program

Day 1 “Tumor immunology & immunotherapy”

09.00 – Registration – Poster installation
09.30 – Opening 

SESSION 01:
Chaiperson: Guido Kroemer

09.35 – Keynote lecture – Bart Lambrecht
Alveolar macrophage-fibroblast crosstalk in the metastatic niche
10.15 – Jérôme Galon
10.40 – Coffee break
11.00 – Rémy Nicolle
A multimodal insight into the microenvironment of pancreatic cancer 
11.25 – Julie Helft
Macrophages and antitumor immunity
11.50 – Elodie Segura
Impact of nutrition on responses to anti-PD1 therapy
12.15 – Lunch break – Poster Session – Visit to sponsors

 

SESSION 02:
Chaiperson: Laurence Zitvogel

13.15 – Partners symposium – Tecan
13.40 – Keynote lecture – Bana Jabri 
Drivers of tissue destruction
14.20 – Chrysothemis Brown
Tolerogenic antigen-presenting cells: coming of age
14.45 – Ignacio Melero
Translating CD137 (4-1BB) agonist agents in combination immunotherapies
15.10 – Ivo Gomperts Boneca
An exopolysaccharide as a Trojan horse for immune modulation of the host response
15.35 – 3 selected abstracts:
Pauline HAMON : TREM2 macrophages are associated with enhanced response to PD-1 blockade in hepatocellular carcinoma
– Salad MOHAMMADNEZHADDARYANI : Targeting eIF4F-depedent mRNA translation to mitigate T cell exhaustion and enhance PD-1 blockade efficacy in melanoma
Anna LLEBARIA-FABRIAS : IL4I1 induces gut and skin dysbiosis promoting melanoma development: modulating skin microbiota to restore anti-tumoral responses

16.20 – Coffee break
16.40 – Janne Lehtiö
Cancer Proteogenomics- Bridging the Genotype – Phenotype Gap with MolecularData

17.05 – Carsten Denkert
Modulation of tumor-microenvironment and biomarker strategies in breast cancer immunotherapy

17.30 – Guido Kroemer
A neuroendocrine factor controlling the cancer-immunity dialogue
17.55 – Seerave Foundation
18.05 – 18.45 – Welcome reception
20.30 – Speakers dinner

Day 2 “Microbiota-immune interface »

SESSION 03:
Chaiperson: Jonathan Pol

09.00 – Keynote lecture – Dan Littman
09.40 – Tim Greten
The Immune Tumor Microenvironment in the Liver
10.05 – Gianluca Ianiro
Targeted fecal microbiota transplantation to boost efficacy of immune checkpoint inhibitors

10.30 – Coffee break
10.50Francesca Gazzaniga
Overcoming microbiome dependent resistance to cancer immunotherapy

11.15 – Benoit Chassaing
Mucus-Associated Microbiota: From Symbiosis to Dysbiosis in Health and Disease
11.40 – Johannes R. Björk
Integrated microbiome-metabolomics analysis reveals associations with diet, concomitant drugs, and ICB response

12.05 – Lunch break – Poster Session – Visit to sponsors

 

SESSION 04:
Chaiperson: Bertrand Routy

13.30 – “Meet the Editors” Session (Cancer Discovery, Cancer Cell, Cell, Nature Cancer, Nature Medicine)
14.30 –
Laurence Albiges
14.55 – Marlies Meisel
Exercise-induced microbiota metabolite enhances cancer immunotherapy efficacy 
15.20 – Giorgio Trinchieri
The gut microbiome as predictor and target for cancer immunotherapy response
15.45 – 3 selected abstracts
– Francesca CORDERO : Functional Profiling of the Cancer-Associated Microbiome: A Constraint-Based Approach to Identifying Core Microbial Communities
Cécile ALANIO : The critical role of the host endogenous compartment after intracerebroventricular CAR T cell therapy in recurrent GBM
François GOLDWASSER : The energetic metabolism of the host predicts the 6-month progression-free and overall survival in lung cancer patients treated with anti-PD1
16.30 – Coffee break
16.50 – Jian Xu
The iMAPS Consortium: addressing microbiome single-cell 6W (What, Who, Why, Wealth, When, Where) by the Meta-ramanomics Platform

17.15 –  Jean-Jacques Trochon
Cancer and metabolic interventions; The proactive role of the patient
17.40 – Bertrand Routy
Strategies to improve the microbiome composition from bench to bedside
18.05 – Laurence Zitvogel
Gut dysbiosis is a risk factor for immunoresistance in oncology and vaccines
18.30 – 18.45 – Closing ceremony